Training requirements to master inhaler devices available in real-life clinical practice
Characteristics of asthma patients at risk of failed Diskus use in primary care
Evaluation of current implementation of BTS/NICE clinical quality standards in community acquired pneumonia (CAP)
Characterising patient pathways to the diagnosis of idiopathic pulmonary fibrosis
Inhaled Corticosteroid And Real life Unlicensed Spacer use (ICARUS)
Identifying opportunities for earlier diagnosis of idiopathic pulmonary fibrosis in routine care in the UK
Extrafine versus fine inhaled corticosteroids in relation to asthma control
Real-life effectiveness evaluation of asthma treatment in Korea
Real-life effectiveness evaluation of budesonide/formoterol (BF) Spiromax for the management of asthma and COPD
The burden of rhinitis in Australia
Real-world effectiveness of extra-fine Ciclesonide (Alvesco®) versus standard particle inhaled corticosteroid (ICS)
An observational evaluation of prescribing of fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist (ICS/LABA): fluticasone propionate / formoterol (FP/FOR) and adverse events in routine primary care at 18-months and 36-months post launch
An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma
Management of Asthma in School age Children On Therapy (MASCOT)
The use of a spacer in the delivery of large (Fluticasone Propionate) and small particle (Qvar®) inhaled corticosteroid (ICS) in asthma
Comparative effectiveness and safety of Ipramol (ipratropium/albuterol) SteriNebs® vs. DuoNeb®
Comparative effectiveness and safety of Salbutamol Sterinebs® vs Ventolin Nebules® in COPD patients
Comparative effectiveness and safety of Budesonide Sterinebs ® vs. Pulmicort Respules ® in a US population of asthma patients
Characterising patients and examining real-life outcomes for UK patients with COPD initiating on or changing to Fostair
Excess costs associated with possible misdiagnosis of Alzheimer’s disease among patients with vascular dementia in a UK CPRD population
Comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease
Benefits of pMDI versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary
Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems
Increased dose of inhaled corticosteroid versus add-on long-acting β-agonist for step-up therapy in asthma
Exacerbation rates in adolescent and adult patients initiating inhaled corticosteroids for asthma: different dose-response profile by particle size
Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide
UK prescribing practices as proxy markers of unmet need in allergic rhinitis
Real life effectiveness and cost impact evaluation of fixed dose combination fluticasone propionate/formoterol (Flutiform®) compared to fluticasone propionate/salmeterol (Seretide®)
Validation of real-life asthma research endpoints
Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD
Real-world effectiveness of extra-fine formulations in Denmark
Switching patients from other inhaled corticosteroid devices to the Easyhaler® in real-life asthma patients
Cardiovascular disease risk associated with exposure to pharmacological smoking cessation interventions in a representative UK primary care patient population
Off-label prescribing and safety of glycopyrronium bromide for symptomatic treatment of severe sialorrhoea (drooling) and/or hyperhidrosis (excessive sweating)
Trends of testing for and diagnosis of alpha-1 antitrypsin deficiency in the UK
Use of degarelix among patients with prostate cancer in daily practice
The effect of DPP-4 inhibitors on asthma control: a potential pathophysiological relationship
Handling Inhalers – Technique Error Comparison (HI-TEC)
Easy Low Instruction Over Time (ELIOT)
Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease
Publications
News & Social Media
#Throwback | Interview with David Price by @Novartis @gerrit_zijlstra at #APSR2016 on what makes a great #MedicalAffairs division! pic.twitter.com/WA9XDRI5xI
— OPRI (@OPRI_SG) November 28, 2016
Are treatment needs being met for #allergicrhinitis patients? Our study says perhaps not: https://t.co/G2EzkmzV6J #oprisg pic.twitter.com/xDbJJRDxcn
— OPRI (@OPRI_SG) January 26, 2017
Professor David Price speaking at the Annual Meeting of Royal College of Otolaryngologist of Thailand pic.twitter.com/dpMPuUKy1T
— OPRI (@OPRI_SG) November 13, 2017
Congrats to David Price for one of the most #highlycited papers in #RespirMed! Read it at: https://t.co/tgux0XuvO6 #inhalertechnique #asthma pic.twitter.com/WIoA8GRZ3e
— OPRI (@OPRI_SG) January 24, 2017
Misdiagnosis of #alzheimersdisease — how high are the costs? Find out at: https://t.co/ui7ThA4STs #oprisg pic.twitter.com/AUAPaOiJPF
— OPRI (@OPRI_SG) January 11, 2017
More photos from the morning symposium at the Annual Meeting of Royal College of Otolaryngologist of Thailand! pic.twitter.com/yEtOfPZzCz
— OPRI (@OPRI_SG) November 14, 2017
Read about the importance of understanding side effects of #NicotineReplacementTherapy when trying to #QuitSmoking: https://t.co/W1KN0bhRve pic.twitter.com/KWxaz96YOI
— OPRI (@OPRI_SG) May 2, 2017
A very successful evening at the #Toowoomba #Education Meeting! @OPCare pic.twitter.com/LWEq0yVhC0
— OPRI (@OPRI_SG) August 4, 2017
David Price from @OPRI_SG at the view by Sydney for the Mastering Allergy & Asthma workshop! pic.twitter.com/Tjk4QxHO9N
— OPRI (@OPRI_SG) September 19, 2017
Omar Usmani, David Price and #mundipharma Chris Chen on inhaler app technology @APSRapsr: Improve technique, adherence and patient outcomes! pic.twitter.com/Mi6ZYwR74c
— OPRI (@OPRI_SG) November 13, 2016
Our abstracts and posters from #ATS2017 are now published! Check them out here: https://t.co/yu9gdqopUa @atscommunity pic.twitter.com/UK2UmKmOwf
— OPRI (@OPRI_SG) May 29, 2017
@OPRI_SG‘s David Price and Japanese Respiratory Society’s Prof Shu Hashimoto, excited to be collaborating on real life research in Japan! pic.twitter.com/7CD73UJehD
— OPRI (@OPRI_SG) December 3, 2016
At the #Melbourne #Education Meeting @OPCare pic.twitter.com/5SfYlw88Ss
— OPRI (@OPRI_SG) August 4, 2017
Prof David Price @RespirologyAPSR talking about the Korean study TRANSffORM pic.twitter.com/jPJNloTlOj
— OPRI (@OPRI_SG) November 13, 2016
David Price having a blast discussing Real World Evidence #RWE #observational trials in #Respiratory medicine with fantastic @Novartis Japan pic.twitter.com/awaD6G7K0I
— OPRI (@OPRI_SG) December 2, 2016
Our paper on #SmokingCessation #NicotineReplacementTherapy is published in Clin Epidemiol @Dovepress! See: https://t.co/jrdY614upb #oprisg
— OPRI (@OPRI_SG) April 27, 2017
A study in @JACIInPractice found the majority of surveyed people with hay fever were not picking optimal over-the-counter medications to treat their symptoms. Read more at: https://t.co/pvlkTMWcNQ
— OPRI (@OPRI_SG) April 4, 2018
Prof David Price at the @GirtonCollege symposium in Singapore to discuss the future of medical research in terms of #RealWorldEvidence, the value of #BigData using large UK databases (such as @OPCare‘s OPCRD), and complex medical ethical issues surrounding the use of such data. pic.twitter.com/tgGoYtDca7
— OPRI (@OPRI_SG) April 24, 2019
Patterns of OTC and prescription OAHs & INCSs for #AllergicRhinitis in real life, published @Dovepress: https://t.co/afAngx8Bsp #oprisg
— OPRI (@OPRI_SG) September 4, 2017
Prof David Price presenting interesting topics at the @Novartis medical booth at @APSR17 on asthma milestones and management goals, and corticosteroid burden with ICS #APSR17 pic.twitter.com/6MPqUScuub
— OPRI (@OPRI_SG) November 27, 2017
New paper on UK #allergicrhinitis patients prescribed MP-AzeFlu by @AllerGKS, David Price, et al. accepted at @BMJ_Open! Congratulations!
— OPRI (@OPRI_SG) February 28, 2017
Prof. David Price at The Rhinology Future Debates, a clinician-orientated meeting established to fill a gap with regard to industry-investor meetings in the field of #Rhinology, organised by @EUFOREA. Read more here: https://t.co/BLS4vIIhNb #AllergicRhinitis #Allergy #EUFOREA pic.twitter.com/Yf1hd4mjY3
— OPRI (@OPRI_SG) February 2, 2018
How does Budesonide Steri-Neb™ fare vs the originator product? Our study now published in #PragmatObsRes @DovePress: https://t.co/WLc1OyKuP1
— OPRI (@OPRI_SG) May 22, 2017
Thank you @mnt for featuring our study! Read more about rescue inhalers here: https://t.co/l6mVhkej9q https://t.co/zG71NVyvFX
— OPRI (@OPRI_SG) April 4, 2018
As featured on @MDMagazine! Read what @OPRI_SG‘s Prof David Price has to say about specialist referral guidelines: https://t.co/MZp2kv7Byy
— OPRI (@OPRI_SG) September 8, 2017
— OPRI (@OPRI_SG) April 2, 2017